Wedbush lowered shares of Unity Biotechnology (NASDAQ:UBX – Free Report) from an outperform rating to a neutral rating in a research note released on Monday morning, The Fly reports. Other equities analysts also recently issued reports about the stock. Citigroup lifted their target price on shares of Unity Biotechnology from $5.00 to $6.00 in a […]